The Anti-obesity Drugs Market will register a CAGR of almost 8% by 2023

Tuesday, December 4, 2018 Obesity News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Dec. 3, 2018 /PRNewswire/ -- 98 pages, November 2018About this marketThe research

on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes. Technavio's
analysts have predicted that the anti-obesity drugs market will register a CAGR of almost 8% by 2023.Download the full report: https://www.reportbuyer.com/product/5638946 Market OverviewGlobal increase in both incidence and prevalence of obesityThe prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.Limited reimbursement for anti-obesity drugsAlthough US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. The bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.For the detailed list of factors that will drive and challenge the growth of the anti-obesity drugs market during the 2018-2022, view our report.Competitive LandscapeThe market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures. Eisai, Novo Nordisk, and Vivus are some of the major companies covered in this report.'With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.'Download the full report: https://www.reportbuyer.com/product/5638946 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-anti-obesity-drugs-market-will-register-a-cagr-of-almost-8-by-2023-300759199.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store